1. Home
  2. NWN vs AGIO Comparison

NWN vs AGIO Comparison

Compare NWN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NWN

Northwest Natural Holding Company

HOLD

Current Price

$53.35

Market Cap

2.2B

Sector

Utilities

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.01

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWN
AGIO
Founded
1859
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
NWN
AGIO
Price
$53.35
$27.01
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$54.33
$39.88
AVG Volume (30 Days)
182.4K
1.0M
Earning Date
05-06-2026
04-29-2026
Dividend Yield
3.65%
N/A
EPS Growth
36.45
N/A
EPS
2.77
N/A
Revenue
$1,289,363,000.00
$43,011,000.00
Revenue This Year
$11.37
$76.75
Revenue Next Year
$4.46
$170.73
P/E Ratio
$19.52
N/A
Revenue Growth
11.83
N/A
52 Week Low
$39.29
$22.24
52 Week High
$55.99
$46.00

Technical Indicators

Market Signals
Indicator
NWN
AGIO
Relative Strength Index (RSI) 48.48 34.32
Support Level $45.72 $26.64
Resistance Level $53.61 $29.69
Average True Range (ATR) 1.01 1.52
MACD -0.23 -0.41
Stochastic Oscillator 21.19 9.27

Price Performance

Historical Comparison
NWN
AGIO

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: